Nutrition

Iron Deficiency on GLP-1: Risk Factors and Prevention

GLP-1 Companion · 8 min read

Iron deficiency is the most common nutritional deficiency worldwide, affecting roughly 2 billion people. It is also among the most underdiagnosed complications of significant caloric restriction and weight loss. As GLP-1 medications produce sustained appetite suppression and dietary changes, iron status deserves systematic attention — particularly in premenopausal women, who begin with higher baseline risk, and in patients who shift away from animal-protein sources.

How GLP-1 Medications Increase Iron Deficiency Risk

Several independent mechanisms converge to elevate iron deficiency risk in GLP-1 users:

• Reduced red meat intake: Heme iron — the most bioavailable form, absorbed at 15–35% efficiency — comes predominantly from red meat and organ meats. GLP-1-mediated appetite suppression frequently reduces or eliminates red meat, particularly fatty cuts that patients find intolerable due to GI side effects.
• Reduced total caloric intake: Lower overall food volume means less dietary iron of all types.
• Delayed gastric emptying: GLP-1 medications slow gastric emptying, which alters the timing and environment of iron absorption in the duodenum. The acidic gastric environment normally converts dietary iron to the ferrous (Fe²⁺) form needed for absorption; extended gastric retention may paradoxically impair this conversion or reduce exposure to the optimal absorption window.
• Reduced gastric acid production: Many GLP-1 users are also on proton pump inhibitors (PPIs) for acid reflux — a common GI complaint on these medications. PPIs significantly reduce gastric acid, and gastric acid is essential for iron absorption. PPI use is an independent risk factor for iron deficiency.
• Inflammation-driven hepcidin elevation: Obesity is a state of chronic low-grade inflammation. Hepcidin — the master regulator of iron absorption — is upregulated by IL-6, an inflammatory cytokine elevated in obesity. Elevated hepcidin reduces duodenal iron absorption and sequesters iron in macrophages, contributing to the "anemia of inflammation" pattern sometimes seen in obesity.

Symptoms of Iron Deficiency on GLP-1

The symptoms of iron deficiency are insidious and overlap with other common experiences during GLP-1 therapy, making attribution difficult:

• Fatigue and low energy: The most prevalent symptom, and easily attributed to caloric restriction or the medication rather than iron deficiency.
• Hair loss (telogen effluvium): Hair loss at 3–6 months of GLP-1 therapy is extremely common and typically attributed to the nutritional stress of rapid weight loss. However, iron deficiency independently causes telogen effluvium. Ferritin below 30 ng/mL is associated with hair loss and is a treatable cause.
• Shortness of breath on exertion: Reduced hemoglobin impairs oxygen delivery, worsening exercise tolerance.
• Cold hands and feet: Impaired peripheral circulation from reduced red cell mass.
• Pallor of the inner eyelids or nail beds.
• Brittle nails or koilonychia (spoon-shaped nails) in more advanced deficiency.
• Pica: Cravings for non-food substances (ice, dirt, starch) — a specific and underrecognized symptom of iron deficiency.
• Cognitive impairment, difficulty concentrating, and brain fog.

Hair loss during GLP-1 therapy is multifactorial. Before accepting it as an inevitable consequence of weight loss, check ferritin, hemoglobin, zinc, and biotin levels. Iron deficiency alone is a correctable cause that is frequently missed.

Ferritin and Hemoglobin: What to Monitor and When

Standard monitoring for iron status includes serum ferritin and a complete blood count (CBC) with hemoglobin. These tests answer different questions:

• Ferritin reflects iron stores. It is the earliest marker to decline in iron deficiency, falling before hemoglobin becomes abnormal. A ferritin below 30 ng/mL indicates depleted stores even if hemoglobin is still normal. Ferritin below 12 ng/mL represents severe depletion.
• Hemoglobin reflects functional iron status. Anemia (hemoglobin below 12.0 g/dL in women, 13.5 g/dL in men) occurs late in the deficiency spectrum when stores are exhausted.
• Serum iron and transferrin saturation can be added for a complete picture, particularly when ferritin is elevated by inflammation and its reliability as a stores marker is in question.

Recommended monitoring schedule for GLP-1 users: baseline ferritin and CBC before starting, then at 6 months and 12 months. Patients with baseline low ferritin (below 50 ng/mL), premenopausal women, vegetarians, and patients with heavy menstrual bleeding should be monitored more frequently — consider 3-month intervals. Bariatric surgery programs routinely monitor iron every 3–6 months; a similar protocol is justified for GLP-1 patients with risk factors.

Dietary Iron Sources: Heme vs Non-Heme

Iron in food comes in two forms with markedly different bioavailability:

• Heme iron (from animal sources): Absorbed at 15–35% efficiency, unaffected by most dietary inhibitors. Best sources: beef liver (3.5 mg per ounce), oysters (8 mg per 3 oz), lean beef (2.5 mg per 3 oz), dark chicken meat (1.1 mg per 3 oz), and canned sardines (2.5 mg per can).
• Non-heme iron (from plant sources): Absorbed at 2–20% efficiency. Absorption is significantly inhibited by calcium, phytates (in whole grains and legumes), and polyphenols (in tea and coffee), and enhanced by vitamin C. Best sources: lentils (6.6 mg per cup cooked), white beans (8 mg per cup cooked), tofu (3 mg per half cup), spinach (3.2 mg per half cup cooked), and fortified cereals.
• Vitamin C dramatically improves non-heme iron absorption — eating an orange or having bell pepper alongside plant iron sources can increase absorption by 2–6-fold.

Iron Supplementation: When and How

When dietary optimization is insufficient to maintain iron stores — which is common in GLP-1 users with documented deficiency — supplementation is indicated. Several formulations are available:

• Ferrous sulfate (325 mg tablet = 65 mg elemental iron): The most widely prescribed and inexpensive form. Can cause significant GI side effects (nausea, constipation, black stools).
• Ferrous gluconate (240 mg tablet = 28 mg elemental iron): Lower elemental iron per tablet but generally better tolerated. Requires more tablets to achieve the same dose.
• Ferrous bisglycinate (iron glycinate): Chelated form with comparable absorption but significantly fewer GI side effects. A reasonable choice for GLP-1 users who already have GI sensitivity.
• Heme iron polypeptide: Derived from animal hemoglobin, very well tolerated, but expensive and less readily available.

Standard repletion dosing is 150–200 mg elemental iron daily, typically divided across 1–2 doses. However, a growing body of evidence suggests that alternate-day iron dosing achieves equivalent or superior absorption compared to daily dosing, because the hepcidin spike triggered by one iron dose suppresses absorption for approximately 24–48 hours. Taking 60–100 mg elemental iron every other day may reduce GI side effects while maintaining efficacy.

Timing Iron Supplements Around GLP-1 Injections

GLP-1 medications are administered subcutaneously and have no direct pharmacokinetic interaction with oral iron absorption pathways. However, timing of iron supplements relative to food and other medications matters significantly:

• Take iron supplements on an empty stomach, ideally 30–60 minutes before meals, for maximum absorption.
• Avoid taking iron within 2 hours of calcium supplements, dairy products, tea, coffee, or antacids — all of which substantially reduce iron absorption.
• If GI side effects are intolerable on an empty stomach, take iron with a small amount of food — this modestly reduces absorption but dramatically improves tolerability.
• Vitamin C (250–500 mg) taken simultaneously with iron enhances non-heme iron absorption even from supplement form.
• The GLP-1 injection day itself does not require any special iron timing adjustments.

The Bottom Line

Iron deficiency is a preventable and correctable condition that is underdiagnosed in GLP-1 users. The convergence of reduced dietary heme iron intake, gastroparesis, and concurrent PPI use creates meaningful risk — particularly for premenopausal women and patients who shift to largely plant-based eating patterns. Systematic monitoring of ferritin and hemoglobin at baseline and at 6 and 12 months, combined with dietary optimization and supplementation when indicated, protects against one of the most impactful and least recognized nutritional complications of GLP-1 therapy.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Drucker DJ (2018). Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metabolism.